Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1918 (LINC01918), known as ROSALIND, is a recently discovered nuclear-encoded lincRNA that localizes to the mitochondrial matrix, where it interacts with mitochondrial ribosomes[2][4][6]. It features a high guanine (G) content, making it unusually susceptible to oxidative modifications. ROSALIND acts as a substrate for mitochondrial ROS, effectively buffering oxidative stress and thus protecting mitochondrial translation machinery from ROS-induced damage. Inhibiting ROSALIND expression leads to increased ROS and protein oxidation, impaired mitochondrial respiration, reduced cancer cell viability, and heightened immunogenicity. Upregulation of ROSALIND is seen in drug-tolerant and recurrent tumors, and its expression can stratify patients by response to immune checkpoint blockade in melanoma. This highlights ROSALIND’s role as a mitochondrial ROS-buffering system and as an emerging marker and potential target in cancer biology[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1918 (LINC01918).